Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06584916
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
None
First Post:
2024-09-03
Brief Title:
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities ATTAIN-MAINTAIN
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 3b Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Orforglipron Once Daily Versus Placebo for Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction
Detailed Description:
All enrolled participants will have completed SURMOUNT-5 I8F-MC-GPHJ NCT05822830 on treatment and meet further eligibility and randomization criteria All endpoints for this study will be evaluated separately per each intervention arm of SURMOUNT-5
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None